论文部分内容阅读
大约有四分之三的乳腺癌都会受到雌激素驱动。一般都会使用抑制雌激素受体活性的药物对这类肿瘤进行治疗,但不幸的是至少一半的病人不会对这些治疗方法产生应答,一旦出现抗药肿瘤病人几乎没有其他治疗选择。现在来自TSRI等研究机构的科学家们发现两个免疫系统分子可能是雌激素驱动乳腺癌出现药物抵抗的关键。研究人员认为他们的发现或打开了开发新治疗方法的大门,或许会影响成千上万雌激素驱动的乳腺癌患者的治疗决策。
About three-quarters of all breast cancers are estrogen-driven. These tumors are typically treated with drugs that inhibit the activity of estrogen receptors, but unfortunately at least half of patients do not respond to these therapies and there is almost no other treatment option for those patients who develop resistant tumors. Now scientists from research institutes such as TSRI have found that two immune system molecules may be the key to estrogen-driven breast cancer drug resistance. Researchers think their discovery or opening the door to developing new treatments may affect the treatment decisions of thousands of estrogen-driven breast cancer patients.